Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | ECE1 | P42892 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4970209 | 1.00 | MME (0.47) | MMETGFBR1ACEECE1CA2 | |
| SCHEMBL30082256 | 0.98 | MME (0.46) | MMETGFBR1ACEECE1CA2 | |
| SCHEMBL30081505 | 0.89 | MME (0.42) | MMETGFBR1ACEECE1 | |
| SCHEMBL29638068 | 0.89 | ECE1 (0.46) | MMETGFBR1ECE1 | |
| SCHEMBL30974405 | 0.88 | MME (0.48) | MMEFOLH1ALDH1A1 | |
| SCHEMBL30440408 | 0.87 | MME (0.40) | MMETGFBR1 | |
| SCHEMBL30082299 | 0.86 | MME (0.39) | MMETGFBR1 | |
| SCHEMBL10773865 | 0.86 | MME (0.43) | MMETGFBR1 | |
| SCHEMBL10773882 | 0.86 | MME (0.43) | MMETGFBR1 | |
| SCHEMBL30946331 | 0.86 | MME (0.43) | MMETGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387431-A1 | TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS THAT BIND TO TRAILSHORT POLYPEPTIDES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-12-25 | — | — | US | claimed |
| EP-4655317-A1 | ANTIBODIES AGAINST MULTIDRUG-RESISTANT KLEBSIELLA PNEUMONIAE | FONDAZIONE TOSCANA LIFE SCIENCES (IT) | 2025-12-03 | — | — | EP | claimed |
| US-12448444-B2 | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof | NOVIMMUNE SA (CH) | 2025-10-21 | — | — | US | claimed |
| US-12441784-B2 | Human antibodies to artemin and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-10-14 | — | — | US | claimed |
| US-20250154261-A1 | MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D, AND CD16, AND METHODS OF USE | DRAGONFLY THERAPEUTICS INC (US) | 2025-05-15 | — | — | US | claimed |
| EP-4543910-A1 | TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS THAT BIND TO TRAILSHORT POLYPEPTIDES | Mayo Foundation for Medical Education and Research (US) | 2025-04-30 | — | — | EP | claimed |
| CN-119735693-A | Proteins binding NKG2D, CD and tumor-associated antigens | 蜻蜓疗法股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119431570-A | Light chain and heavy chain variable region of anti-mycoplasma pneumoniae monoclonal antibody and application thereof | 陕西省人民医院(陕西省临床医学研究院) | 2025-02-14 | — | — | CN | claimed |
| US-20250052755-A1 | FLUORESCENT BIOSENSOR FOR ACETYL COENZYME A | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2025-02-13 | — | — | US | claimed |
| US-12215157-B2 | Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use | DRAGONFLY THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | claimed |
| EP-4367135-A1 | ANTI-ERYTHROPOIETIN ANTIBODY | Andremacon S.r.l. (IT) | 2024-05-15 | — | — | EP | claimed |
| WO-2023250127-A1 | TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS THAT BIND TO TRAILSHORT POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-12-28 | — | — | WO | claimed |
| CN-116253803-A | Polypeptides, photoresist compositions comprising the same, and methods of forming patterns using the same | 三星电子株式会社 | 2023-06-13 | — | — | CN | claimed |
| CN-116217673-A | Polypeptides, photoresist compositions comprising the same, and methods of forming patterns using the same | 三星电子株式会社 | 2023-06-06 | — | — | CN | claimed |
| EP-4175982-A1 | NEUTRALIZING ANTIBODIES TO SARS CORONAVIRUS-2 | FONDAZIONE TOSCANA LIFE SCIENCES (IT) | 2023-05-10 | — | — | EP | claimed |
| WO-2023280391-A1 | ANTI-ERYTHROPOIETIN ANTIBODY | ANDREMACON S.R.L. (IT) | 2023-01-12 | — | — | WO | claimed |
| WO-2023280952-A1 | ANTI-ERYTHROPOIETIN ANTIBODY | ANDREMACON S.R.L. (IT) | 2023-01-12 | — | — | WO | claimed |
| US-20220380459-A1 | MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D, AND CD16, AND METHODS OF USE | DRAGONFLY THERAPEUTICS INC (US) | 2022-12-01 | — | — | US | claimed |
| CN-115368442-A | Polypeptides, photoresist composition including the same, and method of forming pattern using the same | 三星电子株式会社 | 2022-11-22 | — | — | CN | claimed |
| CN-110498851-B | Derivative of antineoplastic protein endostatin and application thereof | 孙嘉琳 | 2022-10-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387431-A1 | TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS THAT BIND TO TRAILSHORT POLYPEPTIDES | TNFRSF9, TNFSF11, CD74 | MME 2419/4885TGFBR1 234/4885ACE 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.